Investigational protease inhibitors as antiretroviral therapies

References

• Konvalinka J, Krausslich HG, Muller B. Retroviral proteases and their roles in virion maturation. Virology. 2015;479-480:403–417.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009;33(4):307–320.
   PubMed Web of Science ®Google Scholar
• Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015.
   Google Scholar
• Holstein A, Plaschke A, Egberts EH. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection. Exp Clin Endocrinol Diabetes. 2001;109(8):389–392.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Chiodo F. Insulin resistance and diabetes mellitus in HIV-infected patients receiving antiretroviral therapy. Metab Syndr Relat Disord. 2004;2(4):241–250.
   PubMed Web of Science ®Google Scholar
• Calvo M, Martinez E. Update on metabolic issues in HIV patients. Curr Opin HIV AIDS. 2014;9(4):332–339.
   PubMed Web of Science ®Google Scholar
• Kumar S, Kumar A. Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs. Alcohol Clin Exp Res. 2011;35(12):2121–2127.
   PubMed Web of Science ®Google Scholar
• Stolbach A, Paziana K, Heverling H, et al. A review of the toxicity of HIV medications II: interactions with drugs and complementary and alternative medicine products. J Med Toxicol. 2015;11(3):326–341.
   PubMed Web of Science ®Google Scholar
• Arbuthnot C, Wilde JT. Increased risk of bleeding with the use of tipranavir boosted with ritonavir in haemophilic patients. Haemophilia. 2008;14(1):140–141.
   PubMed Web of Science ®Google Scholar
• Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl). 2015;7(1):95–104.
   PubMedGoogle Scholar
• Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS clinical trials group. N Engl J Med. 1996;334(16):1011–1017.
   PubMed Web of Science ®Google Scholar
• Vella S. HIV therapy advances. Update on a proteinase inhibitor. AIDS. 1994;8:S25-S30.
   PubMed Web of Science ®Google Scholar
• Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian collaborative ritonavir study group. N Engl J Med. 1995;333(23):1528–1533.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995;333(23):1534–1539.
   PubMed Web of Science ®Google Scholar
• Mathez D, Bagnarelli P, Gorin I, et al. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Antivir Ther. 1997;2(3):175–183.
   PubMedGoogle Scholar
• Schmit JC, Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (APT-538). AIDS. 1996;10(9):995–999.
   PubMed Web of Science ®Google Scholar
• Piroth L, Grappin M, Waldner A, et al. [Discontinuing protease inhibitor treatment of HIV-1 patients for intolerance. Longitudinal study of 309 patients]. Presse Med. 1999;28(8):381–387. French.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA. 1998;280(1):35–41.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337(11):734–739.
   PubMed Web of Science ®Google Scholar
• Boyle BA. Recent advances in the management and treatment of GI and hepatic diseases associated with HIV: part I. AIDS Read. 2001;11(7):354–355, 359–361, 363.
   Google Scholar
• Moyle GJ, Youle M, Higgs C, et al. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol. 1998;38(8):736–743.
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Matsuoka-Aizawa S, Yasuoka A, et al. Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naive patients treated with NFV-containing regimens in an HIV clinic cohort. J Clin Virol. 2003;27(3):252–262.
   PubMed Web of Science ®Google Scholar
• Becker SL. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Expert Opin Investig Drugs. 2003;12(3):401–412.
   PubMed Web of Science ®Google Scholar
• Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35(1):22–32.
   PubMed Web of Science ®Google Scholar
• Masquelier B, Breilh D, Neau D, et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2002;46(9):2926–2932.
   PubMed Web of Science ®Google Scholar
• Wensing AM, Van Maarseveen NM, Nijhuis M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res. 2010;85(1):59–74.
   PubMed Web of Science ®Google Scholar
• De Meyer S, Azijn H, Surleraux D, et al. Tmc114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49(6):2314–2321.
   PubMed Web of Science ®Google Scholar
• McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477–503.
   PubMed Web of Science ®Google Scholar
• Surleraux DL, de Kock HA, Verschueren WG, et al. Design of HIV-1 protease inhibitors active on multidrug-resistant virus. J Med Chem. 2005;48(6):1965–1973.
   PubMed Web of Science ®Google Scholar
• Dierynck I, Van Marck H, Van Ginderen M, et al. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrob Agents Chemother. 2011;55(12):5723–5731.
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Arasteh K, Schurmann D, et al. Antiviral activity, pharmacokinetics, and safety of the HIV-1 protease inhibitor TMC310911, coadministered with ritonavir, in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2014;65(3):283–289.
   PubMed Web of Science ®Google Scholar
• A study to determine the antiviral activity of TMC310911 when administered with ritonavir in treatment-naive human immunodeficiency virus - type 1 (HIV-1) infected patients, NCT00838162. 2013 [cited 2016 Jun 13]. Available from: https://clinicaltrials.Gov/ct2/show/study/nct00838162
   Google Scholar
• Pharmacokinetics, safety & tolerability of isotopologs of atazanavir (ATV), with pharmacokinetic comparison to reyataz, NCT01458769. 2013 [cited 2016 Jun 13]. Available from: https://clinicaltrials.Gov/ct2/show/nct01458769?Term=ctp-518&rank=1
   Google Scholar
• Gulnik EA SV, Eissenstat M, Parkin N, et al. Spi-256, a highly potent HIV protease inhibitor with broad activity against mdr. In: 13th CROI conference on retroviruses and opportunistic infections; 2006 Feb 5–8; Denver (CO).
   Google Scholar
• Abelardo Silva EA, Erickson J, Eissenstat M, et al. Design and crystal structure of SPI-256: an experimental HIV protease inhibitor with a high genetic barrier to resistance. Infect Dis Soc America. 2008 Oct 26;H-1266. [cited 2016 Jul 7]. Available from: https://idsa.confex.com/idsa/2008/webprogram/Paper27769.html
   Google Scholar
• SPI-256. SPI-256: a novel investigational protease inhibitor. 2016 [cited 2016 Jun 13] Available from: http://wwweatgorg/news/162302/SPI-256%3A_a_novel_investigational_protease_inhibitor
   Google Scholar
• Wu JJ, Stranix BR, Milot G, et al. Pl-100, a next generation protease inhibitor against drug-resistant HIV: in vitro & in vivo metabolism. In: 46th annual ICAAC interscience conference on antimicrobial agents and chemotherapy; 2006 Sep 27–30; San Francisco (CA).
   Google Scholar
• Dandache S, Sevigny G, Yelle J, et al. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007;51(11):4036–4043.
   PubMed Web of Science ®Google Scholar
• Dandache S, Coburn CA, Oliveira M, et al. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008;80(12):2053–2063.
   PubMed Web of Science ®Google Scholar
• PPL-100. PPL-100 phase I report: new PI from Merck. 2016 [cited 2016 Jun 13]. Available from: www.natap.org/2006/HIV/121206_05.htm
   Google Scholar
• Ghosh AK, Osswald HL, Prato G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J Med Chem. 2016;59:5172–5208.
   PubMed Web of Science ®Google Scholar
• Tie Y, Boross PI, Wang YF, et al. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol. 2004;338(2):341–352.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Martyr CD, Steffey M, et al. Design of substituted bis-tetrahydrofuran (bis-THF)-derived potent HIV-1 protease inhibitors, protein-ligand X-ray structure, and convenient syntheses of bis-THF and substituted bis-THF ligands. ACS Med Chem Lett. 2011;2(4):298–302.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Chapsal BD, Steffey M, et al. Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors. Bioorg Med Chem Lett. 2012;22(6):2308–2311.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Chapsal BD, Baldridge A, et al. Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation. J Med Chem. 2011;54(2):622–634.
   PubMed Web of Science ®Google Scholar
• Lefebvre E, Schiffer CA. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 2008;10(3):131–142.
   PubMed Web of Science ®Google Scholar
• Shen Y, Altman MD, Ali A, et al. Testing the substrate-envelope hypothesis with designed pairs of compounds. ACS Chem Biol. 2013;8(11):2433–2441.
   PubMed Web of Science ®Google Scholar
• Altman MD, Ali A, Reddy GS, et al. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc. 2008;130(19):6099–6113.
   PubMed Web of Science ®Google Scholar
• Nalam MN, Ali A, Reddy GS, et al. Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. Chem Biol. 2013;20(9):1116–1124.
   PubMed Web of Science ®Google Scholar
• Jones KL, Holloway MK, Su HP, et al. Epsilon substituted lysinol derivatives as HIV-1 protease inhibitors. Bioorg Med Chem Lett. 2010;20(14):4065–4068.
   PubMed Web of Science ®Google Scholar
• Lu D, Sham YY, Vince R. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease. Bioorg Med Chem. 2010;18(5):2037–2048.
   PubMed Web of Science ®Google Scholar
• Dufau L, Marques Ressurreicao AS, Fanelli R, et al. Carbonylhydrazide-based molecular tongs inhibit wild-type and mutated HIV-1 protease dimerization. J Med Chem. 2012;55(15):6762–6775.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26.
   PubMed Web of Science ®Google Scholar
• Kruse CG, Timmerman H. Towards drugs of the future: key issues in lead finding and lead optimization. Amsterdam: IOS Press; 2008.
   Google Scholar
• Pietrucci F, Vargiu AV, Kranjc A. HIV-1 protease dimerization dynamics reveals a transient druggable binding pocket at the interface. Sci Rep. 2015;5:18555.
   PubMed Web of Science ®Google Scholar
• Arya V, Robertson SM, Struble KA, et al. Scientific considerations for pharmacoenhancers in antiretroviral therapy. J Clin Pharmacol. 2012;52(8):1128–1133.
   PubMed Web of Science ®Google Scholar
• Nathan B, Bayley J, Waters L, et al. Cobicistat: a novel pharmacoenhancer for co-formulation with HIV protease and integrase inhibitors. Infect Dis Ther. 2013;2(2):111–122.
   PubMedGoogle Scholar
• Gallant JE, Koenig E, Andrade-Villanueva JF, et al. Brief report: cobicistat compared with ritonavir as a pharmacoenhancer for atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate: week 144 results. J Acquir Immune Defic Syndr. 2015;69(3):338–340.
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2016 [cited 2016 Jun 13] Available from: https://aidsinfo.Nih.Gov/contentfiles/lvguidelines/adultandadolescentgl.Pdf
   Google Scholar
• Putcharoen O, Do T, Avihingsanon A, et al. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS. Drug Des Devel Ther. 2015;9:5763–5769.
   PubMed Web of Science ®Google Scholar
• Wilkin TJ, Taylor B, Olender S, et al. Advances in antiretroviral therapy. Top HIV Med. 2009;17(2):68–88.
   PubMedGoogle Scholar
• A study to evaluate the safety, tolerability and pharmacokinetics of single oral doses of PF-03716539 in healthy adult subjects, NCT00783484. 2009 [cited 2016 Jun 13]. Available from: https://clinicaltrials.Gov/ct2/show/nct00783484
   Google Scholar
• PEPI-TiDP23-C103: first-in-human study to examine the safety, tolerability, and plasma pharmacokinetics of increasing single and repeated oral doses of TMC558445 and of a combined single day dosing of oral TMC558445 and oral TMC310911 and also oral darunavir, NCT00838760. 2010 [cited 2016 Jun 13]. Available from: https://clinicaltrials.Gov/ct2/show/nct00838760
   Google Scholar
• Jonckers TH, Rouan MC, Hache G, et al. Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors. Bioorg Med Chem Lett. 2012;22(15):4998–5002.
   PubMed Web of Science ®Google Scholar
• Kumar S, Jin M, Ande A, et al. Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes. Expert Opin Drug Metab Toxicol. 2012;8(11):1363–1375.
   PubMed Web of Science ®Google Scholar
• Reyskens KM, Essop MF. HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system. Biochim Biophys Acta. 2014;1842(2):256–268.
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6(8):591–602.
   PubMed Web of Science ®Google Scholar
• Ene L, Duiculescu D, Ruta SM. How much do antiretroviral drugs penetrate into the central nervous system? J Med Life. 2011;4(4):432–439.
   PubMedGoogle Scholar
• Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858–883.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Yilmaz A, Cusato J, et al. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. AIDS. 2012;26(12):1529–1533.
   PubMed Web of Science ®Google Scholar
• Nair M, Jayant RD, Kaushik A, et al. Getting into the brain: potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev. 2016;103:202–217.
   PubMed Web of Science ®Google Scholar
• Meshram SM, Kumar YV, Dodoala S, et al. Biodegradable polymeric nanoparticles for delivery of combination of antiretroviral drugs. Int J ChemTech Res. 2015;7(2):716–724.
   Google Scholar
• Jain S, Sharma JM, Jain AK, et al. Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir. Nanomedicine (Lond). 2013;8(10):1639–1655.
   PubMed Web of Science ®Google Scholar
• Destache CJ, Belgum T, Christensen K, et al. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis. 2009;9:198.
   PubMed Web of Science ®Google Scholar
• Singh R, Kesharwani P, Mehra NK, et al. Development and characterization of folate anchored saquinavir entrapped PLGA nanoparticles for anti-tumor activity. Drug Dev Ind Pharm. 2015;41(11):1888–1901.
   PubMed Web of Science ®Google Scholar
• Pedersen JS, Gerstenberg MC. The structure of P85 pluronic block copolymer micelles determined by small-angle neutron scattering. Colloids Surf Physicochem Eng Aspects. 2003;213(2–3):175–187.
   Web of Science ®Google Scholar
• Spitzenberger TJ, Heilman D, Diekmann C, et al. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J Cereb Blood Flow Metab. 2007;27(5):1033–1042.
   PubMed Web of Science ®Google Scholar
• Mahajan SD, Roy I, Xu G, et al. Enhancing the delivery of anti retroviral drug “saquinavir” across the blood brain barrier using nanoparticles. Curr HIV Res. 2010;8(5):396–404.
   PubMed Web of Science ®Google Scholar
• Mahajan SD, Aalinkeel R, Law WC, et al. Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int J Nanomedicine. 2012;7:5301–5314.
   PubMed Web of Science ®Google Scholar
• Puligujja P, McMillan J, Kendrick L, et al. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections. Nanomedicine. 2013;9(8):1263–1273.
   PubMed Web of Science ®Google Scholar
• Puligujja P, Araínga M, Dash P, et al. Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice. Antiviral Res. 2015;120:85–88.
   PubMed Web of Science ®Google Scholar
• Borgmann K, Rao KS, Labhasetwar V, et al. Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons. AIDS Res Hum Retroviruses. 2011;27(8):853–862.
   PubMed Web of Science ®Google Scholar
• Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond). 2009;4(5):557–574.
   PubMed Web of Science ®Google Scholar
• Gupta U, Jain NK. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Deliv Rev. 2010;62(4–5):478–490.
   PubMed Web of Science ®Google Scholar
• Shibata A, McMullen E, Pham A, et al. Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. AIDS Res Hum Retroviruses. 2013;29(5):746–754.
   PubMed Web of Science ®Google Scholar
• Noor MA, Flint OP, Maa JF, et al. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS. 2006;20(14):1813–1821.
   PubMed Web of Science ®Google Scholar
• Carey D, Amin J, Boyd M, et al. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65(9):1878–1888.
   PubMed Web of Science ®Google Scholar
• Cahn PE, Gatell JM, Squires K, et al. Atazanavir–a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chic). 2004;3(3):92–98.
   PubMedGoogle Scholar
• Caron M, Auclair M, Sterlingot H, et al. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS. 2003;17(17):2437–2444.
   PubMed Web of Science ®Google Scholar
• Hui DY. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res. 2003;42(2):81–92.
   PubMed Web of Science ®Google Scholar
• Hresko RC, Hruz PW. HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of gluts with differing affinities for GLUT1 and GLUT4. PLoS One. 2011;6(9):e25237.
   PubMed Web of Science ®Google Scholar
• Hruz PW. HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models. Curr Opin HIV AIDS. 2008;3(6):660–665.
   PubMed Web of Science ®Google Scholar
• Josephson F. Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med. 2010;268(6):530–539.
   PubMed Web of Science ®Google Scholar
• Mallolas J, Sarasa M, Nomdedeu M, et al. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med. 2007;8(2):131–134.
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, El-Sherif O, Bhagani S, et al. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis. 2014;27(1):36–45.
   PubMed Web of Science ®Google Scholar
• Birkus G, Bam RA, Willkom M, et al. Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors. Antimicrob Agents Chemother. 2016;60(1):316–322.
   PubMed Web of Science ®Google Scholar
• Zhu L, Hruska M, Hwang C, et al. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug bms-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects. Antimicrob Agents Chemother. 2015;59(7):3816–3822.
   PubMed Web of Science ®Google Scholar
• Gautam N, Puligujja P, Balkundi S, et al. Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations. Antimicrob Agents Chemother. 2014;58(12):7510–7519.
   PubMed Web of Science ®Google Scholar
• Seden K, Back D, Khoo S. Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. J Antimicrob Chemother. 2009;64(1):5–8.
   PubMed Web of Science ®Google Scholar
• Weber IT, Kneller DW, Wong-Sam A. Highly resistant HIV-1 proteases and strategies for their inhibition. Future Med Chem. 2015;7(8):1023–1038.
   PubMed Web of Science ®Google Scholar
• Kurt Yilmaz N, Swanstrom R, Schiffer CA. Improving viral protease inhibitors to counter drug resistance. Trends Microbiol. 2016;24:547–557.
   PubMed Web of Science ®Google Scholar
• Wong E, Trustman N, Yalong A. HIV pharmacotherapy: a review of integrase inhibitors. JAAPA. 2016;29(2):36–40.
   PubMedGoogle Scholar
• Robertson J, Feinberg J, Darunavir A. nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection. Expert Opin Pharmacother. 2012;13(9):1363–1375.
   PubMed Web of Science ®Google Scholar
• Geretti AM, Moeketsi M, Demasi R, et al. Efficacy of once daily darunavir/ritonavir in PI-Naïve, NNRTI-experienced patients in the ODIN trial. AIDS Res Treat. 2015;2015:1–6.
   Web of Science ®Google Scholar
• Brochot A, Kakuda TN, Van De Casteele T, et al. Model-based once-daily darunavir/ritonavir dosing recommendations in pediatric HIV-1-infected patients aged ≥3 to <12 years. CPT Pharmacometrics Syst Pharmacol. 2015;4(7):406–414.
   PubMedGoogle Scholar
• Ghosh RK, Ghosh SM, Chawla S. Recent advances in antiretroviral drugs. Expert Opin Pharmacother. 2011;12(1):31–46.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Dawson ZL, Mitsuya H. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg Med Chem. 2007;15(24):7576–7580.
   PubMed Web of Science ®Google Scholar
• Burdo TH, Katner SN, Taffe MA, et al. Neuroimmunity, drugs of abuse, and neuroaids. J Neuroimmune Pharmacol. 2006;1(1):41–49.
   PubMed Web of Science ®Google Scholar
• Kolson DL, Lavi E, Gonzalez-Scarano F. The effects of human immunodeficiency virus in the central nervous system. Adv Virus Res. 1998;50:1–47.
   PubMed Web of Science ®Google Scholar
• Gotfredsen A, Podenphant J, Nilas L, et al. Discriminative ability of total body bone-mineral measured by dual photon absorptiometry. Scand J Clin Lab Invest. 1989;49(2):125–134.
   PubMed Web of Science ®Google Scholar
• Akay C, Cooper M, Odeleye A, et al. Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. J Neurovirol. 2014;20(1):39–53.
   PubMed Web of Science ®Google Scholar
• Romao PR, Lemos JC, Moreira J, et al. Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice. Neurotox Res. 2011;19(1):73–80.
   PubMed Web of Science ®Google Scholar
• Gill AJ, Kolson DL. Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in hand persistence. Curr HIV/AIDS Rep. 2014;11(3):325–335.
   PubMed Web of Science ®Google Scholar
• Edagwa BJ, Zhou T, McMillan JM, et al. Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies. Curr Med Chem. 2014;21(36):4186–4198.
   PubMed Web of Science ®Google Scholar
• Kaushik A, Jayant RD, Sagar V, et al. The potential of magneto-electric nanocarriers for drug delivery. Expert Opin Drug Deliv. 2014;11(10):1635–1646.
   PubMed Web of Science ®Google Scholar